Jane Street Group LLC Trims Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Jane Street Group LLC lessened its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 47.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 46,654 shares of the medical equipment provider’s stock after selling 42,190 shares during the period. Jane Street Group LLC owned about 0.10% of BioLife Solutions worth $1,168,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BLFS. State Street Corp raised its position in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the period. Stifel Financial Corp raised its holdings in BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the period. Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions in the 3rd quarter worth $28,000. Rockefeller Capital Management L.P. lifted its position in BioLife Solutions by 81.3% during the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after purchasing an additional 262,504 shares in the last quarter. Finally, FMR LLC grew its holdings in BioLife Solutions by 470.6% during the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 10,983 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $26.59 on Monday. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -25.08 and a beta of 1.91. The firm has a fifty day moving average price of $25.28 and a 200 day moving average price of $23.93. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Insiders Place Their Bets

In related news, EVP Aby J. Mathew sold 25,000 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the sale, the executive vice president now owns 302,046 shares of the company’s stock, valued at $6,394,313.82. This represents a 7.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 64,259 shares of company stock worth $1,424,708 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BLFS shares. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum upped their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.